{"id":254260,"date":"2012-06-27T07:16:40","date_gmt":"2012-06-27T07:16:40","guid":{"rendered":"http:\/\/www.eugenesis.com\/merrimack-pharmaceuticals-to-present-at-the-2012-american-association-for-cancer-research-chemical-systems-biology\/"},"modified":"2012-06-27T07:16:40","modified_gmt":"2012-06-27T07:16:40","slug":"merrimack-pharmaceuticals-to-present-at-the-2012-american-association-for-cancer-research-chemical-systems-biology","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/merrimack-pharmaceuticals-to-present-at-the-2012-american-association-for-cancer-research-chemical-systems-biology.php","title":{"rendered":"Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology &#8230;"},"content":{"rendered":"<p><p>      Two Abstracts Selected for Oral      Presentation    <\/p>\n<p>      Three Posters to be Presented, Each on Different      Examples of Applying the Network Biology      Approach to Therapeutic Development    <\/p>\n<p>      CAMBRIDGE, Mass., June 26, 2012 (GLOBE NEWSWIRE) -- Merrimack      Pharmaceuticals, Inc. (MACK),      a biopharmaceutical company with a pipeline of eight oncology      therapeutics and multiple diagnostics, announced today that      two oral presentations and three posters on its Network      Biology approach to therapeutic development will be presented      at the American Association for Cancer Research (AACR)      Special Conference \"Chemical Systems Biology: Assembling and      Interrogating Computational Models of the Cancer Cell by      Chemical Perturbations\" being held June 27 -- 30, 2012, at      the Marriott Copley Place in Boston, Mass.    <\/p>\n<p>      About Merrimack    <\/p>\n<p>      Merrimack is a biopharmaceutical company discovering,      developing and preparing to commercialize innovative      medicines paired with companion diagnostics for the treatment      of serious diseases, with an initial focus on cancer.      Merrimack applies Network Biology, its proprietary systems      biology-based approach to biomedical research, throughout the      research and development process. Merrimack currently has      five targeted therapeutic oncology candidates in clinical      development.    <\/p>\n<p>      Forward-looking statements    <\/p>\n<p>      Any statements in this press release about Merrimack's future      expectations, plans and prospects constitute forward-looking      statements within the meaning of The Private Securities      Litigation Reform Act of 1995, as amended. Actual results may      differ materially from those indicated by such      forward-looking statements. Merrimack anticipates that      subsequent events and developments will cause its views to      change. However, while Merrimack may elect to update these      forward-looking statements at some point in the future,      Merrimack specifically disclaims any obligation to do so.    <\/p>\n<\/p>\n<p>Read the rest here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/merrimack-pharmaceuticals-present-2012-american-205932257.html;_ylt=A2KJjahSs.pPTlsArFT_wgt.\" title=\"Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology ...\">Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Two Abstracts Selected for Oral Presentation Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development CAMBRIDGE, Mass., June 26, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/merrimack-pharmaceuticals-to-present-at-the-2012-american-association-for-cancer-research-chemical-systems-biology.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254260","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254260"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254260"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254260\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}